Compared to Estimates, Nordson (NDSN) Q3 Earnings: A Look at Key Metrics

Nordson (NDSN) reported strong Q3 2025 results, with revenue reaching $741.51 million, a 12.1% year-over-year increase that surpassed the Zacks Consensus Estimate by 2.85%. Earnings per share (EPS) also exceeded expectations at $2.73, representing a 3.8% positive surprise. While all revenue segments beat analyst estimates, notably Advanced Technology Solutions grew 37.8% and Medical and Fluid Solutions grew 31.6% year-over-year, operating profit performance was mixed across segments. Despite the robust earnings beat, NDSN shares have underperformed the S&P 500 over the past month, returning -0.4% compared to the index's +2%, and currently carry a Zacks Rank #3 (Hold).

Analysis

Nordson (NDSN) delivered a robust third quarter, with revenue of $741.51 million and EPS of $2.73, surpassing analyst consensus estimates by 2.85% and 3.8% respectively. This top-line strength was fueled by significant year-over-year growth in its Advanced Technology Solutions (+37.8%) and Medical and Fluid Solutions (+31.6%) segments. However, a deeper look into the operational metrics reveals a more nuanced performance. The company's largest segment by revenue, Industrial Precision Solutions, saw its net sales decline 5.3% year-over-year, indicating a potential headwind despite beating its quarterly sales estimate. Furthermore, while revenue beats were broad-based, operating profit missed analyst expectations in both the high-growth Advanced Technology and Medical and Fluid Solutions segments, suggesting potential margin pressure or higher-than-expected operational costs in these key growth drivers. This mixed underlying performance likely contributes to the stock's recent underperformance, with a -0.4% return over the past month compared to the S&P 500's +2% gain, and supports its current Zacks Rank #3 (Hold) designation.

Key Decisions for Investors

• Investors should look past the headline earnings beat and scrutinize the segment-level profitability, as the operating profit misses in the high-growth Advanced Technology and Medical and Fluid Solutions segments could signal margin compression.
• The 5.3% year-over-year revenue decline in the largest segment, Industrial Precision Solutions, warrants close monitoring as it may indicate a cyclical or structural weakness that could offset gains in other divisions.
• Given the stock's recent underperformance despite strong top-line results and the mixed operational signals, a neutral stance may be prudent until there is greater clarity on margin trends and a stabilization in the industrial segment.